Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03706833

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System Compared to Abbott MitraClip in Patients With Mitral Regurgitation

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
1,247 (estimated)
Sponsor
Edwards Lifesciences · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

Detailed description

A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT) Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 5 years.

Conditions

Interventions

TypeNameDescription
DEVICEEdwards PASCAL SystemTranscatheter mitral valve repair with the Edwards PASCAL System
DEVICEAbbott Mitraclip SystemTranscatheter mitral valve repair with the Abbott Mitraclip System

Timeline

Start date
2018-11-30
Primary completion
2026-06-30
Completion
2031-06-30
First posted
2018-10-16
Last updated
2026-04-09

Locations

86 sites across 4 countries: United States, Canada, Germany, Switzerland

Regulatory

Source: ClinicalTrials.gov record NCT03706833. Inclusion in this directory is not an endorsement.